Tara Arvedson, Ph.D., is Chief Scientific Officer at Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome. Prior to leading the company’s drug discovery efforts as CSO, Dr. Arvedson served as Senior Vice President of Research at Hexagon. She previously served as an Executive Director of Oncology Research at Amgen where she led small molecule and large molecule programs in oncology, immuno-oncology, inflammation and hematology. During Dr. Arvedson’s 15-year tenure at Amgen, she initiated the company’s KRAS G12C-targeting effort which resulted in the first approved KRAS targeting molecule, LUMAKRAS™ (sotorasib), and drove Amgen’s bispecific T-cell engager platform, which resulted in several clinical candidates. Dr. Arvedson received her Ph.D. in Biochemistry from the California Institute of Technology and was a Damon Runyon Postdoctoral Fellow at the University of California, San Diego.